Containment-Verification Testing For Pharmaceutical Equipment Performance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Containment-Verification Testing For Pharmaceutical Equipment Performance
A Good Practice Guide from the International Society of Pharmaceutical Engineering provides a framework to assess how well pharmaceutical equipment contains hazardous APIs.


Pharmaceutical Technology
Volume 37, Issue 5, pp. s24-s27

The Good Practice Guide: Assessing the Particulate Containment Performance of Pharmaceutical Equipment, from the International Society of Pharmaceutical Engineering (ISPE) describes methodologies for evaluating the containment capability of containment systems and processing equipment in the pharmaceutical and biotechnology industries under defined conditions. (4) This updated guide, first issued in 2005, addresses a broad selection of containment technologies and processing equipment and provides technical guidance and consistent methodologies for evaluating the particulate containment performance (i.e., particulate emissions). The guide defines current good practices and provides information to allow organizations to benchmark their practices and improve on them. Specifically, it provides a methodology to derive data associated with the handling of pharmaceutical ingredients that is useful in the assessment of potential risks. The revised guide was the culmination of a two-year process by the ISPE Containment Community of Practice to revise the original document.

Since first published, the guide has been used by containment-equipment manufacturers, pharmaceutical companies, and industrial-hygiene consultants to perform containment verification assessments for FAT, and/or SAT of containment systems and equipment. It also has been used to evaluate and compare equipment from different suppliers.

Containment-performance-assessment studies

The revised guide identifies crucial issues that need to be addressed prior to, during, and/or at the completion of containment-performance-assessment studies. It guides the user to perform repeatable containment verification testing to assess accurately the containment capabilities of various containment systems and process equipment. Sections provide information and guidance on test protocols, test environment, test material, air and surface sampling, sample analysis, sample interpretation, and reporting.


Table I: Containment equipment test protocols.
The guide specifies a methodology using a surrogate material to verify containment performance and specifies several surrogate materials that may be used, including lactose, naproxen sodium, manitol, acetaminophen (paracetamol), insulin, riboflavin, and sucrose. Of these, lactose and naproxen sodium are the most commonly used. The guide also provides containment equipment test protocols to follow when performing the containment verification assessment. These seven protocols are listed in Table I. As noted previously, prior to selection of a containment system or device, a CPT should be identified for the process, providing the containment system supplier with a containment target for the design and construction of the unit. A CPT should also be identified for off-the-shelf units purchased for use in standard applications such as sample weighing or dispensing. If a CPT has not been established, containment verification testing is still applicable to ensure that unit is providing adequate containment for the activities or processes to be performed within the unit.


Figure 1: Area sampler positions for Protocol 5 Ventilated Enclosure, from ISPE Good Practice Guide. Table II shows the corresponding personal, real-time and surface samples.
The guide outlines containment verification at the supplier’s site (i.e., FAT) and when installed at the user’s site (i.e., SAT). The purpose for containment verification being performed at the supplier’s site is to identify and correct any deficiencies that may impact the meeting of the CPT prior to delivery. Containment performance verification testing should only be performed by qualified industrial hygienists, preferably under the direction of a certified industrial hygienist.


Table II: Sampling details.
The seven protocols in the guide state the recommended positions for air, real-time air monitoring, and surface samples. Figure 1 from the ISPE Good Practice Guide shows the sampler positions for a ventilated enclosure. Protocol 5, Ventilated Enclosure, specifies the sampling locations for performing the containment verification testing.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here